Yes, akathisia is an extrapyramidal symptom (EPS). It sits alongside dystonia, parkinsonism, and tardive dyskinesia as one of the four major types of movement-related side effects caused by medications that block dopamine activity in the brain. What makes akathisia distinct from the other three is that it’s driven as much by an internal feeling as by visible movement.
Where Akathisia Fits Within EPS
Extrapyramidal symptoms are movement problems that arise when drugs interfere with dopamine signaling in the part of the brain responsible for coordinating smooth, voluntary movement. Each EPS subtype looks and feels different:
- Dystonia: involuntary muscle contractions that cause twisting, repetitive movements, or abnormal postures.
- Parkinsonism: tremor, stiffness, slowed movement, and difficulty with balance, resembling Parkinson’s disease.
- Tardive dyskinesia: repetitive, involuntary movements (often of the face, tongue, or jaw) that typically develop after long-term medication use.
- Akathisia: a subjective feeling of inner restlessness paired with semi-purposeful movements like pacing, rocking, or shifting weight from foot to foot.
The key distinction is that dystonia, parkinsonism, and tardive dyskinesia are primarily motor problems you can observe from the outside. Akathisia has an observable motor component too, but the driving force is an intense internal sensation that something is wrong, a compelling need to move that patients often describe as unbearable. A person with akathisia may look merely fidgety to an observer while experiencing severe distress internally. This dual nature (subjective restlessness plus visible movement) is what defines it.
What Causes It
Like other forms of EPS, akathisia is believed to result from blockade of dopamine D2 receptors in the basal ganglia, the brain region that helps regulate movement. Any drug that blocks or depletes dopamine in this area can potentially trigger it.
Antipsychotic medications are the most common cause, particularly older first-generation antipsychotics. Newer second-generation antipsychotics cause less akathisia overall, but the risk still exists and varies between specific drugs. In one study of roughly 300 patients with first-episode schizophrenia, akathisia appeared in 18% of participants.
What many people don’t realize is that antipsychotics aren’t the only culprit. Akathisia is a recognized side effect of antiemetic drugs used for nausea (such as metoclopramide and prochlorperazine) and antidepressants, including SSRIs like fluoxetine, paroxetine, and sertraline. A BMJ case report described a cancer patient whose chemotherapy had to be cancelled because metoclopramide triggered such severe akathisia. Another case involved a patient who developed akathisia after a dose increase of fluoxetine. These non-psychiatric causes are frequently overlooked.
How It Feels Different From Other Conditions
Akathisia is often mistaken for anxiety, agitation, or restless leg syndrome (RLS), and these misdiagnoses can lead to inappropriate treatment that makes things worse.
The difference from RLS comes down to location and sensation. RLS produces an urge to move a specific body part, usually the legs, and is preceded by uncomfortable sensory feelings like crawling or tingling. Movement typically brings relief. Akathisia is more generalized throughout the body, involves more stereotyped movements like pacing or rocking, and moving doesn’t necessarily make the feeling go away. People with akathisia also don’t typically describe the same kind of sensory discomfort in their limbs that RLS patients do.
Distinguishing akathisia from anxiety matters because treating perceived anxiety with an SSRI could actually worsen akathisia if the SSRI is the cause. The hallmark clue is timing: akathisia symptoms start or worsen after beginning a new medication or changing a dose.
When Symptoms Appear
Akathisia follows different timelines depending on the type. Most cases are acute, appearing within days to weeks of starting a medication or increasing the dose, and they tend to be dose-related. Chronic akathisia is defined as symptoms persisting for more than three months after the last dosage change. Tardive akathisia has a delayed onset, with symptoms first appearing three months or more after starting or adjusting a medication, making it harder to connect to the drug that caused it.
Why It Matters Beyond Discomfort
Akathisia is more than an annoyance. Research has found an association between akathisia and higher scores on measures of suicidal thinking, depersonalization (feeling detached from yourself), and agitation. The connection appears to run through depressive mood: the subjective awareness of having akathisia, combined with the distress it causes, can deepen depression and in turn raise the risk of suicidal thoughts. This makes recognizing and treating akathisia early especially important, rather than dismissing it as simple restlessness or anxiety.
How Akathisia Is Managed
The first step is almost always reducing the dose of the medication causing it or switching to an alternative that carries less risk. When that isn’t possible, or when symptoms persist despite the change, several add-on medications can help.
Propranolol, a beta-blocker, is the most studied and widely recommended first-line option. It works through a different pathway than dopamine, targeting the body’s adrenaline system to calm the restlessness. When propranolol can’t be used or doesn’t work, mirtazapine (a type of antidepressant that acts on serotonin and adrenaline receptors) has shown significant improvement in clinical trials and is considered the next best choice. Clonazepam, a benzodiazepine, can provide short-term relief but is generally reserved for brief use because of the risk of tolerance and dependence.
Recognizing akathisia as a true EPS, rather than a vague complaint about restlessness, is critical because the treatment approach is specific. Standard anti-anxiety strategies won’t address the underlying dopamine-related mechanism, and in some cases, they can make the problem worse.